Celcuity (CELC) Free Cash Flow (2016 - 2025)
Celcuity's (CELC) quarterly Free Cash Flow came in at -$36.5 million in Q4 2025, down 31.05% YoY from -$52.9 million in Q4 2024, and up 18.84% on a QoQ basis from -$44.9 million in Q3 2025.
Analysis
Celcuity (CELC) Free Cash Flow (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Free Cash Flow data on file, last reported at -$36.5 million in Q4 2025.
- Quarterly Free Cash Flow fell 31.05% year-over-year to -$36.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$153.5 million (down 83.39% YoY) and the FY2025 annual result came in at -$153.5 million, down 83.39% from the prior year.
- Free Cash Flow climbed to -$36.5 million in Q4 2025, from -$44.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$2.6 million in Q1 2021 to a low of -$44.9 million in Q3 2025.
- A 5-year average of -$17.4 million and a median of -$12.8 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow plunged 384.75% — and 2023, when it gained 14.54%.
- Tracing CELC's Free Cash Flow over 5 years: stood at -$6.1 million in 2021, then tumbled by 56.36% to -$9.6 million in 2022, then sank by 93.6% to -$18.6 million in 2023, then slumped by 49.8% to -$27.8 million in 2024, then slumped by 31.05% to -$36.5 million in 2025.
- The last three Free Cash Flow figures came in at -$36.5 million (Q4 2025), -$44.9 million (Q3 2025), and -$36.3 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -36.45 Mn |
| Sep 30, 2025 | -44.91 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | -27.82 Mn |
| Sep 30, 2024 | -20.61 Mn |
| Jun 30, 2024 | -18.13 Mn |
| Mar 31, 2024 | -17.16 Mn |
| Dec 31, 2023 | -18.57 Mn |
| Sep 30, 2023 | -12.80 Mn |
| Jun 30, 2023 | -9.67 Mn |
| Mar 31, 2023 | -12.87 Mn |
| Dec 31, 2022 | -9.59 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -11.31 Mn |
| Mar 31, 2022 | -5.94 Mn |
| Dec 31, 2021 | -6.13 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -7.64 Mn |
| Mar 31, 2021 | -2.55 Mn |